News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Job Trends
AstraZeneca PLC Not Done With Cost Cuts
November 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (Reuters) - AstraZeneca Plc (AZN.L), facing patent expirations on its top-selling medicines, sees room for more cost cuts in marketing, sales and other areas to shore up profits, its chief executive said on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Job creations
People
AstraZeneca
MORE ON THIS TOPIC
Layoff Tracker
Biogen axes ‘small number’ of Apellis roles after $5.6B buy
June 26, 2026
·
63 min read
·
BioSpace Editorial Staff
Job Trends
10 companies hiring in San Francisco, South San Francisco (plus a few in Brisbane, San Rafael)
June 25, 2026
·
1 min read
·
Chantal Dresner
FDA
BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC
June 24, 2026
·
3 min read
·
Heather McKenzie
Business
Takeda enters transitional year as new CEO seeks return to growth
June 24, 2026
·
2 min read
·
Tristan Manalac
